曲前列尼尔治疗肺动脉高压的循证医学研究进展  

Progress in the development of treprostinil for the treatment of pulmonary hypertension

作　　者：杨其锋 杜敏 李炫逸 何汶俊 苏曦 王健[1] 陈豫钦[1] Yang Qifeng;Du Min;Li Xuanyi;He Wenjun;Su Xi;Wang Jian;Chen Yuqin(The First Affiliated Hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,State Key Laboratory of Respiratory Disease/National Clinical Research Center for Respiratory Disease,Guangdong Key Laboratory of Vascular Disease,Guangzhou 510120,China;Gmu-gibh Joint School of Life Sciences,Guangzhou Medical University,Guangzhou 510120,China)

机构地区：[1]广州医科大学附属第一医院广州呼吸健康研究院呼吸疾病国家重点实验室/国家呼吸系统疾病临床医学研究中心广东省血管疾病重点实验室,广州510120 [2]广州医科大学中国医学科学院广州生物医药与健康研究院联合生命科学学院广州医科大学,广州510120

出　　处：《中华结核和呼吸杂志》2022年第9期930-935,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家自然科学基金(82170069,81800061)。

摘　　要：肺动脉高压是一种进行性加重的肺血管疾病,严重时可引起右心衰竭进而导致患者死亡。曲前列尼尔是一种稳定的前列环素类似物,可强效扩张肺血管,可通过多种途径给药,且半衰期长,稳定性好,治疗范围广。目前临床上被批准用于1型肺动脉高压,但有文献报道曲前列尼尔在3、4型肺动脉高压患者中也有一定疗效。本文就曲前列尼尔治疗1、3、4型肺动脉高压循证医学证据的进展进行综述。Pulmonary arterial hypertension is a progressive pulmonary vascular disease,which can cause right heart failure and even death in severe cases.Treprostinil is a stable prostacyclin analogue and a powerful drug for dilating pulmonary vessels.It can be administered in different ways,with a long half-life,good stability and is suited for diverse types of PAH.It is approved for the treatment of Group 1 PAH,but some studies show that treprostinil is effective in patients with Group 3 or Group 4 PAH.Therefore,this article will review the progress of evidence-based medicine evidence of traprostanil in the treatment of type 1,3 and 4 pulmonary hypertension.

关 键 词：进行性加重 肺血管疾病 曲前列尼尔 肺动脉高压 循证医学证据 前列环素类似物 右心衰竭 文献报道 

分 类 号：R544.1[医药卫生—心血管疾病]